Suchergebnisse - "Jänne, P A"

PubPharm (25)

1

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Boiarsky, D. | Lydon, C. | Chambers, E. | +10

2

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Ricciuti, B. | Alessi, J. | Elkrief, A. | +29

3

Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer : safety run-in results from the FLAURA2 study

enthalten in: ESMO open | 2021

von Planchard, D. | Feng, P. | Karaseva, N. | +10

4

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Hanna, G. | Supplee, J. | Kuang, Y. | +5

5

CNS response to osimertinib in patients with T790M-positive advanced NSCLC : pooled data from two phase II trials

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Goss, G. | Tsai, C. | Shepherd, F. | +12

6

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC) : pooled subset analyses from two randomized trials

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Ramalingam, S. | O'Byrne, K. | Boyer, M. | +7

ErratumIn: Ann Oncol. 2016 Jul;27(7):1363. - PMID 27240994

7

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

enthalten in: Oncogene | 2016

von Yonesaka, K. | Hirotani, K. | Kawakami, H. | +7

8

Targeting HER2 aberrations as actionable drivers in lung cancers : phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Kris, M. | Camidge, D. | Giaccone, G. | +8

9

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

enthalten in: British journal of cancer | 2015

von Jänne, P. | Smith, I. | McWalter, G. | +13

10

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Blumenschein, G. | Smit, E. | Planchard, D. | +16